Eli Lilly

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Eli Lilly 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About LLY

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. 

CEO
David A. Ricks
CEODavid A. Ricks
Employees
50,000
Employees50,000
Headquarters
Indianapolis, Indiana
HeadquartersIndianapolis, Indiana
Founded
1876
Founded1876
Employees
50,000
Employees50,000

LLY Key Statistics

Market cap
965.30B
Market cap965.30B
Price-Earnings ratio
44.47
Price-Earnings ratio44.47
Dividend yield
0.59%
Dividend yield0.59%
Average volume
3.69M
Average volume3.69M
High today
$1,026.22
High today$1,026.22
Low today
$1,007.00
Low today$1,007.00
Open price
$1,015.75
Open price$1,015.75
Volume
2.15M
Volume2.15M
52 Week high
$1,133.95
52 Week high$1,133.95
52 Week low
$623.78
52 Week low$623.78

Stock Snapshot

With a market cap of 965.3B, Eli Lilly(LLY) trades at $1,023.45. The stock has a price-to-earnings ratio of 44.47 and currently yields dividends of 58.8%.

On 2026-02-20, Eli Lilly(LLY) stock moved within a range of $1,007.00 to $1,026.22. With shares now at $1,023.45, the stock is trading +1.6% above its intraday low and -0.3% below the session's peak.

Trading volume for Eli Lilly(LLY) stock has reached 2.15M, versus its average volume of 3.69M.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

Over the past 52 weeks, Eli Lilly(LLY) stock has traded between a high of $1,133.95 and a low of $623.78.

LLY News

Nasdaq 13h
Warning: This Skyrocketing Stock Has a Hidden Risk

Key Points Eli Lilly makes the best-performing GLP-1 drugs on the market today. The company faces intense competition and has a relatively short window of opp...

Warning: This Skyrocketing Stock Has a Hidden Risk
Nasdaq 13h
Prediction: Eli Lilly Stock Could Surge 45% This Year

Eli Lilly (NYSE: LLY) just delivered 45% revenue growth and guided toward $83 billion in 2026 sales. With blockbuster obesity drugs, multiple growth catalysts,...

Prediction: Eli Lilly Stock Could Surge 45% This Year
TipRanks 14h
Eli Lilly initiated with an Overweight at Barclays

Barclays initiated coverage of Eli Lilly (LLY) with an Overweight rating and $1,350 price target The firm sees GLP-1 weight loss treatments as a “durable struct...

Analyst ratings

79%

of 33 ratings
Buy
78.8%
Hold
18.2%
Sell
3%

More LLY News

TipRanks 18h
Eli Lilly announces long-term data on Omvoh in Crohn’s disease

New long-term data from Eli Lilly (LLY) and Company showed Omvoh delivered durable efficacy through three years in adults with moderately to severely active Cro...

TipRanks 19h
Eli Lilly Pushes Into Opioid Use Disorder With New Brenipatide Phase 2 Trial

Eli Lilly And Company (LLY) announced an update on their ongoing clinical study. The RENEW-Op-1 study, officially titled “A Phase 2, Randomized, Double-Blind,...

The Motley Fool 23h
Forget Ozempic: This Obesity‑Drug Giant Is Grabbing the Biggest Slice of the GLP‑1 Gold Rush

Ozempic's rival is generating blockbuster revenue and gaining market share. Everyone has been talking about Ozempic in recent years. You may have seen the name...

Forget Ozempic: This Obesity‑Drug Giant Is Grabbing the Biggest Slice of the GLP‑1 Gold Rush
Simply Wall St 1d
Assessing Eli Lilly Valuation After Recent Share Price Pullback

Advertisement Assessing Eli Lilly after recent performance Eli Lilly (LLY) has drawn attention after a recent share price pullback, with the stock down about...

Assessing Eli Lilly Valuation After Recent Share Price Pullback
Benzinga 2d
Eli Lilly's Landmark Trial Shows Major Psoriasis-Obesity Breakthrough With Taltz-Zepbound Combo

Eli Lilly and Co. (NYSE:LLY) on Wednesday shared topline results from the landmark TOGETHER-PsO open-label Phase 3b trial evaluating the concomitant use of Talt...

Eli Lilly's Landmark Trial Shows Major Psoriasis-Obesity Breakthrough With Taltz-Zepbound Combo
TipRanks 2d
Eli Lilly Stock in Focus as Zepbound Found to Help Treat Psoriasis

Eli Lilly’s (LLY) stock is back in focus on reports that its weight-loss drug Zepbound can help to treat skin conditions such as psoriasis. A late-stage study...

Simply Wall St 2d
Eli Lilly Readies Orforglipron As Broader Pipeline Shapes Valuation Story

Eli Lilly (NYSE:LLY) is preparing for the launch of its oral weight loss pill Orforglipron, backing it with large inventory build up and new manufacturing inves...

Eli Lilly Readies Orforglipron As Broader Pipeline Shapes Valuation Story

People also own

Based on the portfolios of people who own LLY. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.